Federal Trade Commission v. Lundbeck, Inc.
650 F.3d 1236
8th Cir.2011Background
- FTC and Minnesota sued Lundbeck alleging illegal acquisition of NeoProfen violated antitrust and unjust enrichment theories.
- District court bench trial held Lundbeck failed to prove Indocin IV and NeoProfen were in the same product market due to low cross-elasticity of demand.
- PDA treatment has two primary options: Indocin IV (Indomethacin) and NeoProfen (ibuprofen lysine); generics of Indocin IV entered later.
- Pricing history showed Lundbeck substantially increased prices for both drugs after acquiring rights, with higher price differentials than prior to acquisition.
- Evidence relied on testimonials from neonatologists and pharmacists about drug selection being driven by clinical preference rather than price.
- Court affirmed that the district court’s market definition was not clearly erroneous and rejected FTC’s challenges to the factual findings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Properly defined product market for PDA drugs? | FTC contends Indocin IV and NeoProfen are in the same product market. | Lundbeck argues low cross-elasticity and separate markets. | Not clearly erroneous; market defined as separate products. |
| Cross-elasticity as market boundary? | FTC relies on potential hospital switching if price changes, indicating a single market. | District court credited expert showing low cross-elasticity and limited substitution. | District court’s cross-elasticity assessment upheld. |
| Weight of expert evidence on market definition? | FTC argues neonatologists’ views reflect market dynamics and price sensitivity. | Court favored Lundbeck's experts and pharmacologists’ testimony about clinical decision factors. | No clear error in weighing expert testimony. |
| Consideration of practicable alternatives in market delineation? | FTC asserts practicable substitutes support same market. | Court recognized practicable alternatives but found low demand substitution. | Practicable alternatives alone do not create one market. |
| Use of internal Lundbeck documents to define market? | FTC points to strategic focus on NeoProfen as implying competition with Indocin IV. | Lundbeck’s shift could reflect non-interchangeability due to generics risk, not market overlap. | Internal documents not dispositive; multiple permissible views exist. |
Key Cases Cited
- H.J., Inc. v. International Tel. & Tel. Corp., 867 F.2d 1531 (8th Cir. 1989) (cross-elasticity essential to market definition)
- Brown Shoe Co. v. United States, 370 U.S. 294 (Supreme Court 1962) (interchangeability and substitutes define product market)
- Ryko Mfg. Co. v. Eden Servs., 823 F.2d 1215 (8th Cir. 1987) (market determination is a fact question; substantial evidence standard)
- United States v. Cont'l Can Co., 378 U.S. 441 (Supreme Court 1964) (district court fact-finding reviewed for reasonableness and evidence strength)
- Tenet Health Care Corp., 186 F.3d 1045 (8th Cir. 1999) (marginal consumers and price constraints; market evidence must be robust)
- Yamaha Motor Co., Ltd. v. FTC, 657 F.2d 971 (2d Cir. 1981) (hypothetical market considerations are not required for relevant market)
- Engelhard Corp., 126 F.3d 1302 (11th Cir. 1997) (need for concrete evidence to evaluate marginal customer impact)